The global Duloxetine Active Pharmaceutical Ingredients (API) market is expected to grow at a CAGR of 5.2% during the forecast period.
The major depression drug segment accounted for the largest share in the global Duloxetine Active Pharmaceutical Ingredients (API) market in 2017, followed by general anxiety disorder drugs and fibromyalgia drugs. The pharmaceutical industry accounted for the largest share in terms of application in 2017, followed by biotechnology industries and hospitals. North America was estimated to account for the largest share of revenue generated from sales of Duloxetine Active Pharmaceutical Ingredients (API) globally in 2017 due to high prevalence rates of mental disorders such as depression and anxiety disorders among its population.
Some Of The Growth Factors Of This Market:
- The market for Duloxetine API is driven by the increasing prevalence of chronic pain and depression in the population.
- The market for Duloxetine API is driven by the increasing number of patients with chronic pain and depression, which are conditions that can be treated with Duloxetine API.
- The market for Duloxetine API is driven by the increased use of antidepressants to treat chronic pain and depression, which increases demand for Duloxetine API as a raw material in pharmaceutical manufacturing processes.
- The market for Duloxetine API is driven by an increase in research on new treatments that could be used to treat chronic pain and depression, which would increase demand for Duloxetine APIs as a raw material in pharmaceutical manufacturing processes.
- The market for Duloxetine APIs will grow due to an increase in research on new treatments that could be used to treat chronic pain and depression.
Industry Growth Insights published a new data on “Duloxetine Active Pharmaceutical Ingredients (API) Market”. The research report is titled “Duloxetine Active Pharmaceutical Ingredients (API) Market research by Types (Major Depression Drug, Generalized Anxiety Disorder Drug, Fibromyalgia Drugs, Neuropathic Pain Medication, Other, ), By Applications (Pharmaceutical and Biotechnology Industries, Hospital, Other, ), By Players/Companies Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), Shodhana Laboratories (India), Hetero (India), Apotex (Canada), Shionogi (US), Zhejiang Huahai Pharmaceutical (China)”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Duloxetine Active Pharmaceutical Ingredients (API) Market Research Report
By Type
Major Depression Drug, Generalized Anxiety Disorder Drug, Fibromyalgia Drugs, Neuropathic Pain Medication, Other,
By Application
Pharmaceutical and Biotechnology Industries, Hospital, Other,
By Companies
Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), Shodhana Laboratories (India), Hetero (India), Apotex (Canada), Shionogi (US), Zhejiang Huahai Pharmaceutical (China)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Duloxetine Active Pharmaceutical Ingredients (API) Market Report Segments:
The global Duloxetine Active Pharmaceutical Ingredients (API) market is segmented on the basis of:
Types
Major Depression Drug, Generalized Anxiety Disorder Drug, Fibromyalgia Drugs, Neuropathic Pain Medication, Other,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharmaceutical and Biotechnology Industries, Hospital, Other,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Zydus Cadila (India)
- Eli Lilly and Company (United States)
- Shodhana Laboratories (India)
- Hetero (India)
- Apotex (Canada)
- Shionogi (US)
- Zhejiang Huahai Pharmaceutical (China)
 Market Overview.svg)
Highlights of The Duloxetine Active Pharmaceutical Ingredients (API) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Major Depression Drug
- Generalized Anxiety Disorder Drug
- Fibromyalgia Drugs
- Neuropathic Pain Medication
- Other
- By Application:
- Pharmaceutical and Biotechnology Industries
- Hospital
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Duloxetine Active Pharmaceutical Ingredients (API) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Duloxetine is an antidepressant medication that is marketed under the brand name Cymbalta. Duloxetine is a selective serotonin reuptake inhibitor (SSRI).
Some of the major players in the duloxetine active pharmaceutical ingredients (api) market are Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), Shodhana Laboratories (India), Hetero (India), Apotex (Canada), Shionogi (US), Zhejiang Huahai Pharmaceutical (China).
The duloxetine active pharmaceutical ingredients (api) market is expected to grow at a compound annual growth rate of 5.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Duloxetine Active Pharmaceutical Ingredients (API) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Duloxetine Active Pharmaceutical Ingredients (API) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Duloxetine Active Pharmaceutical Ingredients (API) Market - Supply Chain
4.5. Global Duloxetine Active Pharmaceutical Ingredients (API) Market Forecast
4.5.1. Duloxetine Active Pharmaceutical Ingredients (API) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Duloxetine Active Pharmaceutical Ingredients (API) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Duloxetine Active Pharmaceutical Ingredients (API) Market Absolute $ Opportunity
5. Global Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Type
5.3.1. Major Depression Drug
5.3.2. Generalized Anxiety Disorder Drug
5.3.3. Fibromyalgia Drugs
5.3.4. Neuropathic Pain Medication
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Application
6.3.1. Pharmaceutical and Biotechnology Industries
6.3.2. Hospital
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Duloxetine Active Pharmaceutical Ingredients (API) Demand Share Forecast, 2019-2026
9. North America Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Application
9.4.1. Pharmaceutical and Biotechnology Industries
9.4.2. Hospital
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Type
9.7.1. Major Depression Drug
9.7.2. Generalized Anxiety Disorder Drug
9.7.3. Fibromyalgia Drugs
9.7.4. Neuropathic Pain Medication
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Duloxetine Active Pharmaceutical Ingredients (API) Demand Share Forecast, 2019-2026
10. Latin America Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Application
10.4.1. Pharmaceutical and Biotechnology Industries
10.4.2. Hospital
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Type
10.7.1. Major Depression Drug
10.7.2. Generalized Anxiety Disorder Drug
10.7.3. Fibromyalgia Drugs
10.7.4. Neuropathic Pain Medication
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Duloxetine Active Pharmaceutical Ingredients (API) Demand Share Forecast, 2019-2026
11. Europe Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Application
11.4.1. Pharmaceutical and Biotechnology Industries
11.4.2. Hospital
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Duloxetine Active Pharmaceutical Ingredients (API) Market Size and VolumeForecast by Type
11.7.1. Major Depression Drug
11.7.2. Generalized Anxiety Disorder Drug
11.7.3. Fibromyalgia Drugs
11.7.4. Neuropathic Pain Medication
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Duloxetine Active Pharmaceutical Ingredients (API) Demand Share, 2019-2026
12. Asia Pacific Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Application
12.4.1. Pharmaceutical and Biotechnology Industries
12.4.2. Hospital
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Type
12.7.1. Major Depression Drug
12.7.2. Generalized Anxiety Disorder Drug
12.7.3. Fibromyalgia Drugs
12.7.4. Neuropathic Pain Medication
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Duloxetine Active Pharmaceutical Ingredients (API) Demand Share, 2019-2026
13. Middle East & Africa Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Application
13.4.1. Pharmaceutical and Biotechnology Industries
13.4.2. Hospital
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Duloxetine Active Pharmaceutical Ingredients (API) Market Size and Volume Forecast by Type
13.7.1. Major Depression Drug
13.7.2. Generalized Anxiety Disorder Drug
13.7.3. Fibromyalgia Drugs
13.7.4. Neuropathic Pain Medication
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Duloxetine Active Pharmaceutical Ingredients (API) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Duloxetine Active Pharmaceutical Ingredients (API) Market: Market Share Analysis
14.2. Duloxetine Active Pharmaceutical Ingredients (API) Distributors and Customers
14.3. Duloxetine Active Pharmaceutical Ingredients (API) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva Pharmaceutical Industries Ltd (Israel)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sun Pharmaceutical Industries Ltd (India)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Aurobindo Pharma (India)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Lupin (India)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Zydus Cadila (India)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly and Company (United States)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shodhana Laboratories (India)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hetero (India)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Apotex (Canada)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Shionogi (US)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Zhejiang Huahai Pharmaceutical (China)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
